A platform for high-throughput and ultrasensitive immunopeptidomics

This paper presents a semi-automated, high-throughput immunopeptidomics platform that combines optimized 96-well processing with advanced mass spectrometry to achieve ultrasensitive detection of MHC peptides from low-input samples, enabling robust biological discovery in scenarios where cell numbers are limited.

The Gist

Imagine your body is a bustling city, and your immune system is the police force. To keep the city safe, the police need to know exactly what the "bad guys" (like bacteria or viruses) look like. They do this by checking the "wanted posters" displayed on the walls of every building in the city. In biology, these buildings are your cells, and the "wanted posters" are tiny protein fragments called immunopeptides displayed on special flags called MHC molecules.

For years, scientists have wanted to read these posters to find new vaccines or cancer treatments. But there was a huge problem: reading them was like trying to find a specific needle in a haystack, but you had to use a giant, clumsy machine that required a massive haystack (hundreds of millions of cells) just to get a single good look. It was slow, expensive, and impossible to do for rare samples like small biopsies or precious patient tissues.

Enter the new "Smart Library" platform described in this paper.

The researchers built a new, high-tech system that acts like a super-efficient, automated library for finding these tiny protein fragments. Here is how they did it, using simple analogies:

1. The Old Way vs. The New Way

• The Old Way: Imagine trying to find specific books in a library by manually walking through every single aisle, pulling out heavy boxes, and reading them one by one. You needed a massive library (millions of cells) just to find a few interesting books. It took days and was prone to human error.
• The New Way: The team built a 96-lane automated conveyor belt. Instead of one person doing the work, a machine (a positive-pressure device) pushes samples through 96 tiny wells at once. It's like having 96 librarians working in perfect sync.
  • The Trick: They figured out that if you squeeze the "books" (cells) into a tiny, concentrated space (a small drop of liquid) rather than spreading them out in a big bucket, the "librarians" (antibodies) can grab the right "books" (peptides) much faster and more effectively.

2. The "Magic Filter"

The system uses special filters that act like a high-tech sieve.

• First, it catches the "MHC Class I" flags (which show what's happening inside the cell).
• Then, it catches the "MHC Class II" flags (which show what the cell has eaten from the outside).
• Because the machine is so precise, it doesn't lose any of the tiny fragments. It washes away the junk and keeps only the valuable "wanted posters."

3. The Super-Sensitive Camera

Once the machine isolates these tiny fragments, they are sent to a super-powerful camera (a mass spectrometer called the timsTOF SCP).

• The Result: In the past, you needed a whole stadium full of cells to get a clear photo. With this new system, the camera is so sensitive it can take a clear picture of the "wanted posters" from a sample as small as 20,000 cells. That's like finding a specific person in a crowd of 20,000 instead of needing a crowd of 500 million!

4. Catching the "Bad Guys" (Bacteria)

To prove this system works, the researchers infected some immune cells with two types of bacteria: Listeria (food poisoning) and BCG (a tuberculosis vaccine).

• They wanted to see if the new system could find the "wanted posters" of the bacteria hiding inside the cells.
• The Success: Even with a much smaller amount of cells than ever before, the system successfully identified the specific bacterial fragments. It found known "bad guys" and even discovered some new ones. It's like the police force finally got a high-resolution photo of the criminals, even though they only had a tiny amount of evidence to work with.

5. Why This Matters

This new platform is a game-changer for three reasons:

1. Speed: It can process many samples at once (High Throughput).
2. Sensitivity: It works with tiny, precious samples that were previously impossible to study (Ultrasensitive).
3. Accuracy: It gives a clear, quantitative picture of what the immune system is seeing.

In a nutshell:
The researchers turned a slow, clumsy, "big-batch" process into a fast, precise, "micro-scale" assembly line. This means scientists can now study the immune system's "wanted posters" from small biopsies, rare tumors, or limited patient samples, opening the door to better vaccines, personalized cancer therapies, and a deeper understanding of how our bodies fight infection.

Technical Summary

1. Problem Statement

Mass spectrometry (MS)-based immunopeptidomics is critical for discovering vaccine antigens and immunotherapy targets by profiling peptides presented by Major Histocompatibility Complex (MHC) molecules. However, existing workflows face significant limitations:

• High Input Requirements: First-generation workflows often require hundreds of millions of cells, making them unsuitable for scarce clinical samples (e.g., biopsies, rare cell populations).
• Low Throughput & Manual Labor: Traditional methods rely on manual, tube-based immunoprecipitation (IP), which is time-consuming, prone to variability, and difficult to scale.
• Trade-off: Recent advancements have improved either sensitivity (for low input) or throughput, but rarely both simultaneously. There is a critical need for a unified platform that combines high sensitivity with high-throughput automation.

2. Methodology

The authors developed a semi-automated, miniaturized immunopeptidomics workflow designed for 96-well plates, optimized for both MHC Class I and Class II peptides.

• Sample Preparation & Automation:
  • Lysis: Cells are lysed in a highly concentrated, small volume (100 µL) of mild lysis buffer to maximize protein concentration, which was found to be a critical factor for IP efficiency.
  • Immunoprecipitation (IP): The workflow utilizes a Tecan Resolvex® A200 positive-pressure device to automate washing and elution steps.
  • Sequential Capture: MHC Class I and Class II complexes are captured sequentially on 96-well filter plates containing cross-linked antibodies (W6/32 for MHC-I and PdV5.2 for MHC-II). The sequential order (MHC-I first, then MHC-II) prevents cross-contamination.
  • Elution & Purification: Peptides are eluted with 10% acetic acid and purified using Sep-Pak tC18 plates.
• Mass Spectrometry:
  • Analysis is performed on a timsTOF SCP mass spectrometer.
  • Acquisition Mode: Data-Dependent Acquisition (DDA) coupled with PASEF (Parallel Accumulation–Serial Fragmentation).
  • Optimization: Specific ion mobility-m/z polygons ("Thunder" for MHC-I and broad for MHC-II) are used to select precursors, enhancing the detection of low-abundance peptides.
• Data Analysis:
  • A multi-search engine workflow (MSFragger, Comet, Sage, PEAKS) followed by TIMS2Rescore is used for peptide identification.
  • Binding predictions are generated using NetMHCpan-4.1 (Class I) and NetMHCIIpan-4.3 (Class II).
  • Quantitative analysis uses FragPipe and IonQuant with statistical testing via limma.

3. Key Contributions

• Unified High-Throughput/Ultra-Sensitive Platform: The study successfully bridges the gap between throughput and sensitivity, enabling the processing of samples ranging from 32 million down to 20,000 cells in a 96-well format.
• Optimized Miniaturization: By reducing lysis volume to 100 µL and utilizing positive pressure for flow control, the platform minimizes sample loss and adsorption, significantly boosting sensitivity compared to gravity-flow or tube-based methods.
• Validation of Low-Input Limits: The authors demonstrated that the platform can recover nearly 300 predicted MHC-I binders from as few as 20,000 cells, a 10- to 50-fold reduction in input compared to previous standard workflows.
• Quantitative Biological Discovery: The platform supports robust quantitative comparisons, allowing for the detection of differential peptide presentation during infection.

4. Key Results

• Performance on Standard Inputs (JY Cells):
  • From 16 million JY cells (the identified optimal input), the workflow identified >13,500 MHC-I and >6,000 MHC-II peptides.
  • Peptide identification numbers plateaued around 16 million cells, indicating diminishing returns beyond this point.
  • High-quality binding motifs and sequence logos were recovered, confirming the specificity of the enrichment.
• Ultra-Sensitive Limits:
  • From 20,000 JY cells, the platform identified 1,244 peptides, including 292 predicted MHC-I binders.
  • A "core" subset of 236 peptides was consistently identified across all dilution series, demonstrating reproducibility even at ultra-low inputs.
  • The proportion of predicted binders was actually higher at lower inputs, suggesting the workflow favors the detection of high-affinity, high-abundance peptides.
• Bacterial Antigen Discovery:
  • The platform was applied to U937 macrophages infected with Listeria monocytogenes and Bacillus Calmette-Guérin (BCG) using 16 million cells.
  • Listeria: Identified 50 high-confidence bacterial peptides from 35 proteins, including known virulence factors (e.g., hly/LLO, OppA, inlC).
  • BCG: Identified 41 bacterial peptides from 32 proteins, including groEL2, groES, and hupB.
  • These results matched findings from previous studies that used 30-fold higher cell inputs, validating the platform's sensitivity.
• Host Immunopeptidome Remodeling:
  • Quantitative analysis of BCG-infected cells revealed significant upregulation of host peptides involved in inflammation (e.g., IL-1β), phagocytosis (Fcγ receptors), and immune signaling, demonstrating the platform's utility for studying host-pathogen interactions.

5. Significance

This work represents a major advancement in immunopeptidomics by providing a robust, automated, and scalable solution for analyzing limited biological samples.

• Clinical Applicability: The ability to work with low cell inputs (down to 20,000 cells) makes immunopeptidomics feasible for precious clinical specimens like tumor biopsies, lymph node samples, and rare immune cell populations, which were previously inaccessible.
• Biosafety and Efficiency: The reduced cell requirement lowers the biosafety burden for studying high-risk pathogens (e.g., Mycobacterium tuberculosis) by requiring fewer infected cells, while the 96-well format enables high-throughput screening of multiple conditions and replicates.
• Future Directions: The platform lays the groundwork for personalized cancer vaccine development and rapid antigen discovery for emerging pathogens, combining the sensitivity of modern MS instrumentation with optimized, miniaturized sample preparation.